Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,520.36
(
0.02%
)
US TECH 100
29,106.40
(
-0.25%
)
Dow Jones
50,644.28
(
0.36%
)
Brent Oil
93.90
(
1.58%
)
Bitcoin
73,383.04
(
-2.01%
)
News Focus
News Focus
Post# of 518864
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

WilliamMunny

Send PM Follow Ignore
Followers 8
Posts 494
Boards Moderated 0
Alias Born 03/06/2022

WilliamMunny

Re: boi568 post# 494887

Friday, 07/25/2025 10:29:17 AM

Friday, July 25, 2025 10:29:17 AM

Post# of 518864
As a holder of AVXL, I am glad to have it reconfirmed that not all SIGMAR1 agonists are created equal. As to efficacy, Blarcamesine beat the SOC, LEQEMBI and Kisunla, (not to mention safety, cost, and practical delivery).
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News